PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after…

By J. Wood, G. Bold, E. Buchdunger, R. Cozens, S. Ferrari, J. Frei, F. Hofmann, J. Mestan, H. Mett, T. O'reilly and 17 more. Cancer Research, 2000

869 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. (2008, background): “As a consequence, short-term xenograft models are of limited value in comparing various small molecule angiokinase inhibitors, each with a distinct profile of VEGFR, PDGFR, and FGFR inhibition, with the VEGF-specific antibody bevacizumab (41), or vatalanib (37), a prototype first-generation VEGFR ki”
Novel Antiangiogenic Effects of the Bisphosphonate Compound Zoledronic Acid (2002, methodology): “Porous chambers containing bFGF (0.3 (cid:1) g/ml) or VEGF (2 (cid:1) g/ml) in 0.8% (w/v) heparinized agar were implanted subcutaneously in female mice.”
Annexin 1: a new paracrine agent secreted by a novel mechanism (2002, unknown): “PTK787 from Novartis (Wood et al. 2000), or SU5416 from Sugen (Fong et al.”
Vascular Endothelial Growth Factor and Angiogenesis (2004, background): “They mainly block several subtypes of the VEGFR and also other tyrosine kinase receptors such as KIT, PDGF receptor, fibroblast growth factor receptor 1, Tie-2, and FLT3 (Laird et al., 2000, 2002; Wedge et al., 2000; Wood et al., 2000).”